The FDA just approved the world’s first clinical trial of a Zika vaccine. The tests will determine whether or not the vaccine is safe for use in normal, healthy people – however, they will not be able to determine whether or not the vaccine prevents the disease. The vaccine, called GLS-5700, has been shown to cause a strong antibody response against the Zika virus in monkeys and mice. With any luck, the results of this new study will be available by the end of the year.

Continue reading below
Our Featured Videos
zika, zika virus, zika infection, zika vaccine, vaccines, dna vaccines, experimental drugs, drug trial, vaccine trial, clinical trial

The trial will be run by Inovio Pharmaceuticals, a company specializing in immunotherapy, and GeneOne Life Science, a DNA vaccine developer. It will begin in just a few short weeks, and it will include 40 adult subjects. If successful, the vaccine may be tested in people who have an existing Zika infection in later trials.

GLS-5700 is what is known as a “DNA vaccine,” a relatively new approach to fighting disease. Instead of directly injecting parts of the infectious agent, it consists of DNA coded to produce a special protein that surrounds the Zika virus. The vaccine is injected the same way as a normal shot, and it’s also zapped with a device that delivers a short electrical pulse to help guide the DNA into the patient’s cells. Once this process is complete, the new DNA trains the immune system of the patient to fight the disease.

Related: Millions of genetically altered mosquitoes are being released in the Cayman Islands to fight Zika

This may be the first Zika vaccine approved for testing, but it isn’t the only one being developed. The National Institute of Allergy and Infectious Diseases is also in the process of developing a DNA vaccine, which may begin phase 1 testing as soon as August. However, it’s important to note that clinical testing is a long and complex process, and that it might still be years yet before either of these vaccines are ready for the mass market.

Via The Verge

Photos via Tom and Oregon State University